 BioQuadrant presently has four Discovery Programs running. We are actively developing a portfolio of intellectual property in the following areas: |  Our discovery platform is a chemistry-based platform, and is aimed at the development of small-molecule drugs and peptide mimetics with improved pharmacokinetic properties. We are actively seeking strategic alliances and collaborative research opportunities with companies whose strengths are complementary and additive to our own. Our goal is to establish long-term relationships with companies strong in computer-aided drug design and screening. Learn more |
 Our Discovery Program relies heavily on the use of novel, synthetic specialty building blocks which we use to assemble novel drug-like molecules. We are developers and manufacturers of unnatural prolines, tetrahydro-beta-carbolines, benzimidazoles, benzodiazepine-diones, amino-azepanones, as well as pharmaceutical intermediates and conjugation tools. Learn more |
||